Prospect News: News for Sarepta Therapeutics, Inc.

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with S > Issuers starting with S, CV only > All stories on Sarepta Therapeutics, Inc. > Stories on Sarepta Therapeutics, Inc., CV only

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Sarepta Therapeutics, Inc.

3/18/2025	CV	Market Commentary: Sarepta convertible notes in focus, gain on hedge as stock drops; Lucid improves
3/18/2025	CV	Market Commentary: Morning Commentary: Sarepta convertible notes in focus, improve on hedge as stock drops
6/21/2024	CV	Market Commentary: Hertz clears the convertible primary market with first PIK note in decades; Sarepta jumps
6/21/2024	CV	Market Commentary: Morning Commentary: Hertz clears the convertible primary market with first PIK note in decades
10/31/2023	CV	Market Commentary: Western Digital spinoff complicates convertibles offering; Sarepta, Spirit, JetBlue drop
10/31/2023	CV	Market Commentary: Morning Commentary: Western Digital spinoff complicates convertible notes offering
6/29/2023	CV	Market Commentary: American Water exchangeables lower on bond move; Sarepta gains; Greenbriar outperforms
6/29/2023	CV	Market Commentary: Morning Commentary: Sarepta convertible notes active amid recent stock volatility
5/24/2023	CV	Market Commentary: Duke, CMS, Welltower hit new lows; Sarepta, PTC Therapeutics down outright, up on swap
5/15/2023	CV	Market Commentary: Sarepta convertibles soar on FDA fast-track status for drug; Bloom Energy regains par
5/15/2023	CV	Market Commentary: Morning Commentary: Sarepta convertibles soar on FDA fast-track status for drug
3/17/2023	CV	Market Commentary: Convertibles quiet amid volatility; Alliant, Southern Co. active; Sarepta up on swap
3/17/2023	CV	Market Commentary: Morning Commentary: Sarepta convertible notes in focus as stock plunges in early trading
12/21/2022	CV	Market Commentary: Pebblebrook Hotel Trust convertibles fall on slashed guidance; Sarepta hits new heights
12/21/2022	CV	Market Commentary: Morning Commentary: Sarepta convertibles show early gains on strong day for equities
11/28/2022	CV	Market Commentary: MicroStrategy convertible notes for sale; Sarepta gains; Southwest Airlines active
10/18/2022	CV	Market Commentary: Convertibles secondary firms; Sarepta hits new high, expands dollar-neutral; MongoDB up
10/18/2022	CV	Market Commentary: Morning Commentary: Sarepta convertible notes hit new outright high; MongoDB gains
9/27/2022	CV	Market Commentary: Convertibles secondary quiet amid volatility; high-grade notes active; Sarepta weakens
9/27/2022	CV	Market Commentary: Morning Commentary: Sarepta convertible notes active early, weaken dollar-neutral
9/21/2022	CV	Market Commentary: Convertibles secondary prepositions for Fed; Zendesk buyout trades continue; DISH up
9/21/2022	CV	Market Commentary: Morning Commentary: Sarepta convertible notes active ahead of Fed decision on rates
9/19/2022	CV	Sarepta greenshoe lifts 1.25% five-year convertibles to $1.15 billion
9/19/2022	CV	Market Commentary: Royal Caribbean convertible notes hit new high; DISH weaker; Sarepta notes contract
9/19/2022	CV	Market Commentary: Morning Commentary: Sarepta convertible notes continue to gain on quiet morning
9/15/2022	CV	Market Commentary: NextEra equity units contract on debut; Sarepta convertibles add outright; Alnylam gains
9/14/2022	CV	Market Commentary: NextEra on tap; Sarepta convertibles in focus, expand on debut; Alnylam, iQIYI active
9/14/2022	CV	Market Commentary: Morning Commentary: Sarepta convertible notes in focus early, expand on trading debut
9/14/2022	CV	New Issue: Sarepta prices $1 billion five-year convertible notes to yield 1.25%, up 35%
9/13/2022	CV	Market Commentary: Sarepta convertibles eyed; Alnylam flat outright, expands on swap; Wayfair falls
9/13/2022	CV	Market Commentary: Morning Commentary: Alnylam convertibles flat outright, expand on swap; Sarepta eyed
9/12/2022	CV	Market Commentary: Sarepta on tap; Alnylam offering oversubscribed; Wayfair gains continue; Nio, Li Auto up
9/12/2022	CV	Sarepta talks $1 billion five-year convertible notes to yield 1.25%-1.75%, up 32.5%-37.5%
1/8/2021	CV	Market Commentary: Summit Hotel convertibles soar on debut; Sarepta tanks outright, jumps dollar-neutral
1/8/2021	CV	Market Commentary: Morning Commentary: Summit Hotel convertibles upsized, trade up on debut; Sarepta eyed
12/13/2019	CV	Market Commentary: Biotech space firm; Sarepta convertible skyrockets; Ionis notes gain; Lumentum up again
12/13/2019	CV	Market Commentary: Morning Commentary: Sarepta convertible notes break double par; biotech space firm
11/14/2018	CV	Market Commentary: Great Ajax on tap; Wayfair eyed, old convertibles contract; HC2 prices; Sarepta active
6/19/2018	CV	Market Commentary: Sarepta convertibles skyrocket; PTC Therapeutics drops; Canopy gains; Sea, Twitter active
11/13/2017	CV	Market Commentary: Rambus, Quotient announce new deals, Square Inc. jumps, recent issues in demand
11/10/2017	CV	Market Commentary: Convertibles secondary market stable despite new issues, increased credit spreads
11/10/2017	CV	Market Commentary: Morning Commentary: Sarepta trades actively again with convertibles, shares higher; chip names eyed
11/10/2017	CV	Sarepta greenshoe lifts 1.5% seven-year convertibles to $570 million
11/9/2017	CV	Market Commentary: New deals from Sarepta, Insulet trade high on reputation, new issuance drought
11/9/2017	CV	Market Commentary: Morning Commentary: Sarepta’s upsized 1.5% notes ‘well received’ in market debut
11/8/2017	CV	Market Commentary: Insulet, Arbor Realty deals hit market; Sarepta upsizes deal; GNC and Aegean Marine plummet
11/8/2017	CV	New Issue: Sarepta Therapeutics sells upsized $475 million seven-year convertibles at 1.5%, up 40%
11/8/2017	CV	Market Commentary: Morning Commentary: New Insulet 1.375% convertibles trade above par, high demand
11/7/2017	CV	Market Commentary: Apollo add-on active in trading, Insulet deal upsized, Sarepta Therapeutics plans new deal
11/7/2017	CV	Sarepta Therapeutics talks $375 million seven-year convertible notes to yield 1.5%-2%, up 35%-40%
11/7/2012	CVHYPF	Sarepta Therapeutics files automatic shelf for stock, preferreds, debt

©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.